Outlook Therapeutics (@outlooktx) 's Twitter Profile
Outlook Therapeutics

@outlooktx

$OTLK is a late clinical stage biopharma company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications.

ID: 1267537712535547906

linkhttps://outlooktherapeutics.com/ calendar_today01-06-2020 19:25:49

354 Tweet

668 Followers

121 Following

Outlook Therapeutics (@outlooktx) 's Twitter Profile Photo
Outlook Therapeutics
@outlooktx

5 months ago

We are working to redefine the standard of care in anti-VEGF, a large and growing market. Learn more: bit.ly/3RkpyHY $OTLK #retinadisease #ophthalmology

We are working to redefine the standard of care in anti-VEGF, a large and growing market. Learn more: bit.ly/3RkpyHY $OTLK #retinadisease #ophthalmology